发明申请
US20100197688A1 EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
审中-公开
EPHA4 RTK抑制剂治疗神经病学和神经损伤性疾病和癌症
- 专利标题： EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
- 专利标题（中）： EPHA4 RTK抑制剂治疗神经病学和神经损伤性疾病和癌症
-
申请号： US12473810申请日： 2009-05-28
-
公开(公告)号： US20100197688A1公开(公告)日： 2010-08-05
- 发明人: Philippe G. Nantermet , Hamaka A. Rajapakse , Takeshi Sagara , John M. Sanders , Hong Zhu
- 申请人： Philippe G. Nantermet , Hamaka A. Rajapakse , Takeshi Sagara , John M. Sanders , Hong Zhu
- 主分类号： A61K31/472
- IPC分类号： A61K31/472 ; C07D217/02 ; C07D401/12 ; C07C237/40 ; C07D413/12 ; C07D413/14 ; C07D409/12 ; C07D203/16 ; C07D295/12 ; C07D235/04 ; C07D231/56 ; C07D277/62 ; C07D473/00 ; C07D471/04 ; A61K31/4725 ; A61K31/5377 ; A61K31/52 ; A61K31/496 ; A61K31/47 ; A61K31/517 ; A61P25/00 ; A61P25/28 ; A61P25/16 ; A61P9/10 ; A61P17/06 ; A61P27/02
摘要：
The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.
信息查询
IPC分类:
